

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|---|--------------------------|-------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/441,140 |
| | | Filing Date | November 16, 1999 |
| | | First Named Inventor | Beka SOLOMON |
| | | Group Art Unit | 1647 |
| | | Examiner Name | C. Nichols |
| | | Attorney Docket Number | SOLOMON=1R |
| Sheet | 1 | of | 1 |

| Examiner Initials* | Cite No. ¹ | Document Number | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|-----------------|-----------------------------------|-----------------------------|---|---|
| | | Number | Kind Code ² (if known) | | | |
| CSO | FU | US 00/201,430 | | 11/30/1998 | Schenk | |
| | | US 00/497,553 | | 02/03/2000 | Schenk | |
| | | US 00/724,477 | | 11/28/2000 | Schenk | |
| | | US 00/700,927 | | 11/28/2000 | Schenk | |
| | | US 00/724,702 | | 11/28/2000 | Schenk | |
| | | US 00/724,480 | | 11/28/2000 | Schenk | |
| | | US 00/724,480 | | 11/28/2000 | Schenk | |
| | FV | US 00/322,200 | | 05/28/1999 | Schenk | |
| | | US 00/723,743 | | 11/27/2000 | Schenk | |
| | | US 00/723,760 | | 11/27/2000 | Schenk | |
| | | US 00/724,240 | | 11/27/2000 | Schenk | |
| | | US 00/729,304 | | 11/27/2000 | Schenk | |
| | | US 00/724,495 | | 11/27/2000 | Schenk | |
| | FW | US 00/360,845 | | 05/26/2000 | Schenk | |
| | | US 00/724,040 | | 11/28/2000 | Schenk | |
| | | US 00/724,064 | | 11/28/2000 | Schenk | |
| | FX | US 00/680,018 | | 05/26/2000 | Schenk et al. | |
| | | US 00/724,662 | | 11/28/2000 | Schenk et al. | |
| | | US 00/723,544 | | 11/28/2000 | Schenk et al. | |
| | | US 00/724,273 | | 11/28/2000 | Schenk et al. | |
| | | US 00/724,551 | | 11/28/2000 | Schenk et al. | |
| | | US 00/724,285 | | 11/28/2000 | Schenk et al. | |
| | FY | US 00/306,010 | | 05/28/00 | Schenk et al. | |
| | | US 00/726,700 | | 11/28/2000 | Schenk et al. | |
| | | US 00/724,291 | | 11/28/2000 | Schenk et al. | |
| | | US 00/70,704 | | 03/13/2004 | Schenk | |

CONSIDERED; DO NOT PRINT.

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----------------------|---------------------------|---------------------|-----------------------------------|-----------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Number | | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| CSO | FZ | WO | 00/72880 A2 & A3 | | 12-07-2000 | Neuralab Limited | | |

| | | | |
|--------------------|-------------------|-----------------|--------|
| Examiner Signature | <i>C. Nichols</i> | Date Considered | 5/6/04 |
|--------------------|-------------------|-----------------|--------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|---|------|--------------------------|------------------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 09/441,140 |
| | | Filing Date | November 16, 1999 |
| | | First Named Inventor | Beka SOLOMON |
| | | Group Art Unit | 4542 1647 |
| | | Examiner Name | G. Bassal NICHOLS |
| Sheet 1 | of 2 | Attorney Docket Number | SOLOMON=1R |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|----------------------|----------------------|---|--|---|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code (if known) | | | |
| CSO | AE | 5,750,349 | A | Suzuki et al | 05-12-1998 | |
| | AF | 5,753,624 | A | McMichael et al | 05-19-1998 | |
| | AG | 5,851,996 | A | Kline | 12-22-1998 | |
| CSO | AH | 5,955,317 | A | Suzuki et al | 09-21-1999 | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|-----------------------|----------|---|--|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Number | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Office ³ | Number | | | |
| CSO | AI | WO | 95/31996 | A1 | MILKHAUS LABORATORY | 11-30-1995 |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | | | | |
|---|-----------------------|--|--|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | | | T ² |
| CSO | AJ | DELIMASTRO et al, "Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration", <u>Vaccine</u> 15(11):1276-1285 (1997) | | | | |
| | AK | DODART et al, "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model", <u>Nat Neurosci</u> 5(5):452-457 (2002) (published online April 8, 2002, pp. 1-6) | | | | |
| | AL | JANUS et al, "A β peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease", <u>Nature</u> 408(6815):979-982 (2000) | | | | |
| | AM | MANOUTCHARIAN et al, "Phage Displayed Biomolecules As Preventive and Therapeutic Agents", <u>Curr Pharm Biotechnol</u> 2(3):217-223 (2001) | | | | |
| | AN | MORGAN et al, "A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease" <u>Nature</u> 408(6815):982-985 (2000) | | | | |
| | AO | SEUBERT et al, "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids", <u>Nature</u> 359(6393):325-327 (1992) | | | | |
| | AP | Elan Internet Press Release, "Elan and AHP provide an update on the phase 2A Clinical Trial of AN-1792", January 18, 2002 (www.elan.com/NewsRoom) | | | | |
| CSO | AQ | Elan Internet Press Release, "Elan and Wyeth provide update on status of Alzheimer's collaboration", May 2002 (www.elan.com/NewsRoom) | | | | |


| | | | |
|--------------------|-------------------|-----------------|---------|
| Examiner Signature | <i>G. Nichols</i> | Date Considered | 7/30/02 |
|--------------------|-------------------|-----------------|---------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

RECEIVED
AUG 28 2002

TECH CENTER 1600/2900



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 8

Complete if Known

| | |
|------------------------|-------------------------|
| Application Number | 09/441,140 |
| Filing Date | November 16, 1999 |
| First Named Inventor | Beka SOLOMON |
| Group Art Unit | 1642 1647 |
| Examiner Name | S. Unger NICHOLS |
| Attorney Docket Number | SOLOMON=1R |

U.S. PATENT DOCUMENTS


| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
| | | Number | Kind Code ² (if known) | | | |
| ES | AR | 6,417,178 | B1 | Klunk et al | 07-09-2002 | |
| | AS | 6,284,221 | B1 | Schenk et al | 09-04-2001 | |
| | AT | 6,262,335 | B1 | Hsiao et al | 07-17-2001 | |
| | AU | 6,114,133 | - | Seubert et al | 09-05-2000 | |
| | AV | 5,958,883 | - | Snow | 09-28-1999 | |
| | AW | 5,955,079 | - | Mond et al | 09-21-1999 | |
| | AX | 5,877,399 | - | Hsiao et al | 03-02-1999 | |
| | AY | 5,869,093 | - | Weiner et al | 02-09-1999 | |
| | AZ | 5,869,054 | - | Weiner et al | 02-09-1999 | |
| | BA | 5,849,298 | - | Weiner et al | 12-15-1998 | |
| | BB | 5,837,473 | - | Maggio et al | 11-17-1998 | |
| | BC | 5,780,587 | - | Potter | 07-14-1998 | |
| | BD | 5,744,368 | - | Goldgaber et al | 04-28-1998 | |
| | BE | 5,736,142 | - | Sette et al | 04-07-1998 | |
| | BF | 5,733,547 | - | Weiner et al | 03-31-1998 | |
| | BG | 5,679,348 | - | Nesburn et al | 10-21-1997 | |
| | BH | 5,645,820 | - | Haller et al | 07-08-1997 | |
| | BI | 5,641,474 | - | Haller et al | 06-24-1997 | |
| | BJ | 5,641,473 | - | Haller et al | 06-24-1997 | |
| | BK | 5,612,486 | - | McConlogue et al | 03-18-1997 | |
| | BL | 5,605,811 | - | Seubert et al | 02-25-1997 | |
| | BM | 5,585,100 | - | Mond et al | 12-17-1997 | |
| | BN | 5,571,500 | - | Haller et al | 11-05-1996 | |
| | BO | 5,571,499 | - | Haller et al | 11-05-1996 | |
| | BP | 5,441,870 | - | Seubert et al | 08-15-1995 | |
| | BQ | 5,434,170 | - | Andrulis, Jr. | 07-18-1995 | |
| | BR | 5,387,742 | - | Cordell | 02-07-1995 | |
| | BS | 5,270,165 | - | Van Nostrand et al | 12-14-1993 | |
| | BT | 5,231,170 | - | Averback | 07-27-1993 | |
| | BU | 5,231,000 | - | Majocha et al | 07-27-1993 | |
| | BV | 5,220,013 | - | Ponte et al | 06-15-1993 | |
| | BW | 5,208,036 | - | Eppstein et al | 05-04-1993 | |
| | BX | 5,192,753 | - | McGeer et al | 03-09-1993 | |
| | BY | 5,187,153 | - | Cordell et al | 03-09-1993 | |
| | BZ | 5,057,540 | - | Kensil et al | 10-15-1991 | |
| | CA | 5,004,697 | - | Pardridge | 04-20-1991 | |
| ES | CB | 4,666,829 | - | Glenner et al | 05-19-1987 | |

RECEIVED
 NOV 15 2002
 FED CENTER
 600 2000

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 7/30/03 |
|--------------------|--------------------|-----------------|---------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2

of 8

Complete if Known

| | |
|------------------------|-----------------------------|
| Application Number | 09/441,140 |
| Filing Date | November 16, 1999 |
| First Named Inventor | Beka SOLOMON |
| Group Art Unit | 1642 1647 |
| Examiner Name | S. Unger NICHOLS |
| Attorney Docket Number | SOLOMON=1R |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Number | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ² |
|--------------------|-----------------------|-----------------------|-----------|-----------------------------------|---|--|---|----------------|
| | | Office ³ | Number | Kind Code ⁵ (if known) | | | | |
| GSO | CC | WO | 94/28412 | A1 | The Miriam Hospital | 12-08-1994 | | |
| | CD | WO | 94/03615 | A1 | Medeva Holdings B.V. | 02-17-1994 | | |
| | CE | WO | 94/01772 | A1 | Children's Med. Cen. Corp. | 01-20-1994 | | |
| | CF | EP | 0 276 723 | B1 | Bayer AG | 12-08-1993 | | Yes |
| | CG | WO | 93/21950 | A1 | Medeva Holdings B.V. | 11-11-1993 | | |
| | CH | WO | 93/16724 | A1 | Autoimmune, Inc. | 09-02-1993 | | |
| | CI | WO | 93/15760 | A1 | Mond et al | 08-19-1993 | | |
| | CJ | WO | 93/14200 | A1 | TSI Corporation | 07-22-1993 | | |
| | CK | WO | 93/04194 | A1 | Regents of U. of Minn. | 03-04-1993 | | |
| | CL | WO | 93/02189 | A1 | Regents of U. of Cal. | 02-04-1993 | | |
| | CM | WO | 92/13069 | A1 | Imp. Col. of Sci, Tech. & Med. | 08-06-1992 | | |
| | CN | WO | 92/06708 | A1 | Brigham and Women's Hosp. | 04-30-1992 | | |
| | CO | WO | 92/06187 | A1 | The Upjohn Company | 04-16-1992 | | |
| | CP | WO | 91/19810 | A1 | California Biotechnology Inc. | 12-26-1991 | | |
| | CQ | WO | 91/16819 | A1 | Molecular Rx, Inc. | 11-14-1991 | | |
| | CR | EP | 0 451 700 | A1 | Miles Inc. | 10-16-1991 | | |
| | CS | WO | 91/12816 | A1 | Autoimmune, Inc. | 09-05-1991 | | |
| | CT | WO | 91/08760 | A1 | Brigham and Women's Hosp. | 06-27-1991 | | |
| | CU | WO | 90/12871 | A1 | Res. Found. Mental Hygiene, Inc. | 11-01-1990 | | |
| | CV | WO | 90/12870 | A1 | Res. Found. Mental Hygiene, Inc. | 11-01-1990 | | |
| CW | GB | 2 220 211 | A | Ribi Immunochem Research Inc. | 01-04-1990 | | | |
| CX | WO | 89/06689 | A1 | McLean Hosp. Corp. & U. Roch. | 07-27-1989 | | | |
| CY | WO | 89/06242 | A1 | McLean Hosp. Corp. & U. Roch. | 07-13-1989 | | | |
| CZ | WO | 89/03687 | A1 | Genetics Institute, Inc. | 05-05-1989 | | | |
| DA | WO | 89/01343 | A1 | Regents of U. of Cal. | 02-23-1989 | | | |
| DB | WO | 88/10120 | A1 | Brigham and Women's Hosp. | 12-29-1988 | | | |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|--|----------------|
| GSO | DC | BARROW et al, "Solution Conformations and Aggregational Properties of Synthetic Amyloid β -Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" J Mol Biol 225(4):1075-1093 (1992) | |

Examiner Signature


G. Mises

Date Considered

11/30/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 8

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 09/441,140 |
| Filing Date | November 16, 1999 |
| First Named Inventor | Beka SOLOMON |
| Group Art Unit | 4042-1647 |
| Examiner Name | S. Unger NICHOLS |
| Attorney Docket Number | SOLOMON=1R |

TECH CENTER 1501/2100
NOV 15 2002

RECEIVED

| | |
|----|---|
| DD | BAUER et al, "Interleukin-6 and α -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <u>FEBS Lett</u> 285(1):111-114 (1991) |
| DE | BICKEL et al, "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <u>Soc for Neuroscience Abstracts</u> 18:764 (325.6) (1992) |
| DF | BODMER et al, "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem Biophys Res Comm</u> 171(2):890-897 (1990) |
| DG | BORIS-LAWRIE et al, "Recent advances in retrovirus vector technology," <u>Curr Opin Genet Dev</u> 3(1):102-109 (1993) |
| DH | BRICE et al, "Absence of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," <u>J Neurol Neurosurg Psychiatry</u> 56:112-113 (1993) |
| DI | CAPUTO et al, "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <u>Clin Neuropharm</u> 15(S1):414A-415A (1992) |
| DJ | CHAO et al, "Transforming Growth Factor- β Protects Human Neurons Against β -Amyloid-Induced Injury," 23 rd Annual Meeting, Washington, DC, November 7-12, 1993, <u>Soc Neurosci Abstracts</u> 19:513.7 (1993) |
| DK | CHEN et al "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <u>Neurosci Lett</u> 125(2):223-226 (1991) |
| DL | CORDELL B " β -Amyloid formation as a potential therapeutic target for Alzheimer's disease," <u>An. Rev Pharmacol Toxicol</u> 34:69-89 (1994) |
| DM | COSTA et al, "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand J Immunol</u> 38:177-182 (1993) |
| DN | ELIZAN et al, "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J Neurol Sci</u> 59(3):341-347 (1983) |
| DO | FELSENSTEIN et al, "Processing of the β -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neurosci Lett</u> 152:185-189 (1993) |
| DP | FISHER et al, "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <u>Proc Natl Acad Sci</u> 88:1779-1782 (1991) |
| DQ | GANDY et al, "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TIPS</u> 13:108-113 (1992) |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 7/30/03 |
|--------------------|--|-----------------|---------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



RECEIVED

NOV 15 2002

TECH CENTER 1600/200


| | | | |
|--|------------------------|----------------------|-------------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Application Number | 09/441,140 |
| | | Filing Date | November 16, 1999 |
| | | First Named Inventor | Beka SOLOMON |
| | | Group Art Unit | 1642-1647 |
| | | Examiner Name | S. Ungar <i>NICHOLS</i> |
| Sheet 4 of 8 | Attorney Docket Number | SOLOMON=1R | |

| | | | |
|-----|----|---|--|
| 600 | DR | GARDELLA et al, "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <u>Biochem Biophys Res Comm</u> 173:1292-1298 (1990) | |
| | DS | GASKIN et al, "Human antibodies reactive with β -amyloid protein in Alzheimer's disease," <u>J Exp Med</u> 177:1181-1186 (1993) | |
| | DT | GLENNER et al, "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochem Biophys Res Comm</u> 120(3):885-890 (1984) | |
| | DU | GLENNER et al, "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochem Biophys Res Comm</u> 122(3): 1131-1135 (1984) | |
| | DV | GOATE et al, "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> 349:704-706 (1991) | |
| | DW | GORTNER, <u>Outlines of Biochemistry</u> , 3 rd Ed, Gorner et al Eds., John Wiley & Sons, Inc New York, pp. 322-323, (1949) | |
| | DX | HAASS et al "Amyloid β -peptide is produced by cultured cells during normal metabolism," <u>Nature</u> 359(6393):322-5 (1992) | |
| | DY | HAGA et al, "Synthetic Alzheimer amyloid β /A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Res</u> 601:88-94 (1993) | |
| | DZ | HARRINGTON et al, "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β /A4-protein," <u>Biochim Biophys Acta</u> 1158(2):120-128 (1993) | |
| | EA | HAZAMA et al, "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of <i>Escherichia Coli</i> Heat-Labile Enterotoxin and Interleukin-2", <u>Immunology</u> 78:643-649 (1993) | |
| | EB | HILBICH et al, "Human and rodent sequence analogs of Alzheimer's amyloid β A4 share similar properties and can be solubilized in buffers of pH 7.4," <u>Eur J Biochem</u> 201:61-69 (1991) | |
| | EC | HUBERMAN et al, "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J Neuroimmunol</u> 52(2):147-152 (1994) | |
| | ED | IKEDA et al, "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- β protein monoclonal antibody," <u>Lab Invest</u> 57(4):446-449 (1987) | |
| 650 | EE | ITAGAKI et al, "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J Neuroimmunol</u> 24:173-182 (1989) | |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 7/30/03 |
|--------------------|--------------------|-----------------|---------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



RECEIVED
 NOV 13 2002
 TECH CENTER


| | | | |
|--|------------------------|----------------------|-------------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Application Number | 09/441,140 |
| | | Filing Date | November 16, 1999 |
| | | First Named Inventor | Beka SOLOMON |
| | | Group Art Unit | 1042-1647 |
| | | Examiner Name | S. Ungar <i>NICHOLS</i> |
| Sheet 5 of 8 | Attorney Docket Number | SOLOMON=1R | |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| CSO ↓ CSO | EF | WATSUBO et al, "Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species Is Aβ42(43)," <u>Neuron</u> 13:45-53 (1994) | 1 |
| | EG | JANSEN et al, "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immunol Rev</u> 62:185-216 (1982) | 1 |
| | EH | JOACHIM et al, "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am J Pathol</u> 138(2):373-384 (1991) | 1 |
| | EI | KALARIA RN, "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <u>Res Immunol</u> 143:637-641 (1992) | 1 |
| | EJ | KAWABATA et al, "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> 354:476-478 (1991) | 1 |
| | EK | LAMPERT-ETCHELLS et al, "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993) | 1 |
| | EL | LANGER, "New Methods of Drug Delivery," <u>Science</u> 249:1527-1532 (1990) | 1 |
| | EM | LANNFELT et al, "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behav Brain Res</u> 57(2):207-213 (1993) | 1 |
| | EN | LOPEZ et al, "Serum auto-antibodies in Alzheimer's disease," <u>Acta Neurol Scand</u> 84(5):441-444 (1991) | 1 |
| | EO | MAJOCHA et al, "Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vivo Imaging of Amyloid Angiopathy," <u>J Nuc Med</u> 33:2184-2189 (1992) | 1 |
| | EP | MAK et al, "Polyclonals to β-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <u>Brain Res</u> 667:138-142 (1994) | 1 |
| | EQ | MASTERS et al, "Amyloid plaque core protein in Alzheimer disease and Down syndrome," <u>Proc Natl Acad Sci USA</u> 82:4245-4249 (1985) | 1 |

| | |
|---|----------------------------|
| Examiner Signature <i>G. Nichols</i> | Date Considered 7/30/03 |
|---|----------------------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 8

Complete if Known

| | |
|------------------------|-------------------------|
| Application Number | 09/441,140 |
| Filing Date | November 16, 1999 |
| First Named Inventor | Beka SOLOMON |
| Group Art Unit | 1642 (left) |
| Examiner Name | S. Ungar NICHOLS |
| Attorney Docket Number | SOLOMON=1R |

RECEIVED
 NOV 15 2002
 PATENT CENTER 1601/2300


RECEIVED

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|---|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| <div style="font-size: 2em;">}</div> | ER | McGEER et al, "Immunohistochemical Localization of Beta-Amyloid Precursor Protein Sequences in Alzheimer and Normal Brain Tissue by Light and Electron Microscopy," <u>J Neurosci Res</u> 31:428-442 (1992) | |
| | ES | MILLER et al, "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J Exp Med</u> 174:791-798 (1991) | |
| | ET | MORI et al, "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <u>J Biol Chem</u> 267(24):17082-17088 (1992) | |
| | EU | MORRIS et al, "The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)," <u>Neurology</u> 39:1159-1165 (1989) | |
| | EV | MURPHY et al, "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am J Pathol</u> 144(5):1082-1088 (1994) | |
| | EW | NEWCOMBE et al, "Solubility characteristics of isolated amyloid fibrils," <u>Biochim Biophys Acta</u> 104:480-486 (1965) | |
| | EX | PARDRIDGE et al, "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem Biophys Res Comm</u> 146:307-313 (1987) | |
| | EY | PRIEELS et al, "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406t (1994) | |
| | EZ | QUON et al, "Formation of β -Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> 352:239-241 (1991) | |
| | FA | ROGERS et al, "Complement activation by β -amyloid in Alzheimer Disease," <u>Proc Natl Acad Sci USA</u> , 89:1-5 (1992) | |
| FB | ROSSOR et al, "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Ann of NY Acad Sci</u> , 695:198-202 (1993) | | |
| FC | RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976) | | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 7/30/03 |
|--------------------|--|-----------------|---------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

Complete if Known

| | |
|-------------------------------|-------------------------|
| Application Number | 09/441,140 |
| Filing Date | November 16, 1999 |
| First Named Inventor | Beka SOLOMON |
| Group Art Unit | 1042 Koff |
| Examiner Name | S. Ungar NICHOLS |
| Attorney Docket Number | SOLOMON=1R |

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 7 | of | 8 |
|-------|---|----|---|

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| CSW | FD | SAIDO et al, "Spatial Resolution of the Primary β-Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J Biol Chem</u> 269(21):15253-15257 (1994) | |
| | FE | SAIDO et al, "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J Biol Chem</u> 268(33):25239-25243 (1993) | |
| | FF | SAITOH et al, "Immunological Analysis of Alzheimer's Disease Using Anti-β-protein Monoclonal Antibodies," <u>Sapporo Med J</u> 60:309-320 (1991) | |
| | FG | SELKOE DJ "Alzheimer's Disease: A Central Role for Amyloid," <u>J Neuropathol Exp Neurol</u> 53(5): 438-447 (1994) | |
| | FH | SELKOE DJ, "Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease," <u>Trends Neurosci</u> , 16(10):403-409 (1993) | |
| | FI | SELKOE DJ, "Alzheimer's disease. In the Beginning....," <u>Nature</u> 354(6353):432-433 (1991) | |
| | FJ | SELKOE DJ, "Amyloid Protein and Alzheimer's Disease," <u>Sci Am</u> 265(5):68-78 (1991) | |
| | FK | SELKOE DJ, "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> 6(4):487-498 (1991) | |
| | FL | SHIOSAKA S "Attempts to make models for Alzheimer's disease," <u>Neurosci Res</u> 13(4):237-255 (1992) | |
| | FM | TRIEB et al, "Is Alzheimer β amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <u>Immunobiology</u> , 191(2-3):114-115 Abstract C.37 (1994) | |
| | FN | VAN GOOL et al, "Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <u>Neurosci Lett</u> 172:122-124 (1994) | |
| CSW | FO | VERBEEK et al, "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <u>Am J Pathol</u> 144(1):104-116 (1994) | |

RECEIVED
NOV 18 2002
TECH CENTER 1600/2900

| | |
|---|----------------------------|
| Examiner Signature <i>G. Nichols</i> | Date Considered 7/30/03 |
|---|----------------------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.




| | | | |
|--|------|------------------------|-----------------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Application Number | 09/441,140 |
| | | Filing Date | November 16, 1999 |
| | | First Named Inventor | Beka SOLOMON |
| | | Group Art Unit | 1642 1642 |
| | | Examiner Name | S. Unger NICHOLS |
| Sheet 8 | of 8 | Attorney Docket Number | SOLOMON=1R |

| | | | |
|-----------------------|----|--|---|
| ↓ ↓ ↓ ↓ ↓ | FP | WEINER et al, "Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Annu Rev Immunol</u> 12:809-837 (1994) | / |
| | FQ | WONG et al, "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <u>Proc Natl Acad Sci USA</u> 82:8729-8732 (1985) | / |
| | FR | <u>New York Times National</u> , "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94) | / |
| | FS | Wisconsin Alumni Research Foundation, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep 70(24), 56. (June 19, 1969) | / |
| | FT | Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (1969) | / |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

RECEIVED
 NOV 15 2002
 TECH CENTER 1600/2900

| | | | |
|--------------------|--------------------------------|-----------------|---------|
| Examiner Signature | <i>[Handwritten Signature]</i> | Date Considered | 7/30/03 |
|--------------------|--------------------------------|-----------------|---------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

| Complete if Known | |
|------------------------|------------------------------|
| Application Number | 09/441,140 |
| Filing Date | November 16, 1999 |
| First Named Inventor | Beka SOLOMON |
| Group Art Unit | 1642 1647 |
| Examiner Name | G. Bonsel NICHOLS |
| Attorney Docket Number | SOLOMON=1R |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code ² (if known) | | | |
| CJD | AA | 5,786,180 | | König et al | 07-28-1998 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |


RECEIVED
 MAR 06 2002
 TECH CENTER 1500/2900

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----------------------|-----------------------|-----------|-----------------------------------|---|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Number | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁸ |
| | | Office ³ | Number | Kind Code ⁵ (if known) | | | | |
| AB | EP | | 0 613 007 | A3 | Brems et al | 08-31-1994 | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

| | | | |
|--------------------|--|-----------------|-----------|
| Examiner Signature | | Date Considered | 7/30/2003 |
|--------------------|--|-----------------|-----------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449 PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|--------------------|
| Application Number | 09/441,140 |
| Filing Date | November 16, 1999 |
| First Named Inventor | Beka SOLOMON |
| Group Art Unit | 1642-1647 |
| Examiner Name | G. Boneal- NICHOLS |
| Attorney Docket Number | SOLOMON=1R |

Sheet 2 of 2

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|--|----------------|
| CS | AC | FRIEDLAND et al, "Development of an Anti-A β Monoclonal Antibody for In Vivo Imaging of Amyloid Angiopathy in Alzheimer's Disease", <u>Mol Neurobiol</u> 9(1-3):107-113 (1994) | |
| CS | AD | WALKER et al, "Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody", <u>J Neuropathol Exp Neurol</u> 53(4):377-383 (1994) | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Examiner Signature: *[Handwritten Signature]* Date Considered: 7/30/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.